Skip to main content

Table 4 Extension-phase baseline (week 12) to week 24 changes in fatigue and related symptoms

From: Improvement in multiple dimensions of fatigue in patients with fibromyalgia treated with duloxetine: secondary analysis of a randomized, placebo-controlled trial

Assessment

Duloxetine/Duloxetine

(n= 176)

Placebo/Duloxetine

(n= 187)

 

Baseline mean (SD)

Mean change (SE)

Baseline mean (SD)

Mean change (SE)

Multidimensional Fatigue Inventory

    

   General Fatigue

14.6 (3.8)

-0.61 (0.3)a

15.5 (3.7)

-1.02 (0.3)a

   Mental Fatigue

13.1 (3.9)

-0.43 (0.3)

13.8 (4.2)

-0.32 (0.3)

   Physical Fatigue

10.6 (4.1)

-0.41 (0.2)

11.7 (4.3)

-0.51 (0.2)a

   Reduced Activity

11.9 (4.3)

-0.29 (0.3)

12.8 (4.2)

-0.64 (0.3)a

   Reduced Motivation

10.2 (3.9)

-0.71 (0.3)a

11.2 (3.8)

-0.49 (0.3)

BPI average pain

4.1 (2.3)

-0.56 (0.2)a

4.9 (2.4)

-0.66 (0.2)a

Anxiety

2.2 (2.5)

-0.43 (0.2)a

3.1 (2.8)

-0.45 (0.2)a

Mood

2.2 (2.6)

-0.54 (0.2)a

3.1 (2.7)

-0.83 (0.2)a

Sleep difficulties

4.6 (3.1)

-0.81 (0.2)a

5.1 (2.9)

-1.12 (0.2)a

Stiffness

4.4 (2.7)

-0.67 (0.2)a

5.2 (2.7)

-0.82 (0.2)a

  1. aSignificant (P ≤ 0.05) within-group improvement, mixed-effects model repeated measures analysis. BPI average pain, Brief Pain Inventory [15] 24-hour average pain item; SD, standard deviation; SE, standard error.